Long-term outcome of immunologic autograft engineering.
Luis F PorrataDavid J InwardsStephen M AnsellIvana N MicallefPatrick B JohnstonJose C VillasboasJonas PaludoSvetomir N MarkovicPublished in: EJHaem (2022)
Our phase III trial reported that autograft-absolute lymphocyte count (A-ALC) improved survival post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short-term follow-up of 2 years. We evaluated retrospectively in our phase III trial patients that the A-ALC still confers survival benefit with a longer follow-up. With a median follow-up of 127.6 months, patients infused with an A-ALC ≥ 0.5 × 10 9 cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224-0.687, p < 0.001) and progression-free survival (HR = 0.413, 95% CI: 0.253-0.677), p < 0.0004). This study supports that A-ALC provides long-term survival benefit post APBHSCT.
Keyphrases
- phase iii
- free survival
- clinical trial
- peripheral blood
- open label
- end stage renal disease
- phase ii
- newly diagnosed
- ejection fraction
- double blind
- peritoneal dialysis
- study protocol
- prognostic factors
- randomized controlled trial
- stem cells
- patient reported outcomes
- placebo controlled
- bone marrow
- signaling pathway
- acute myeloid leukemia
- cell therapy
- cell proliferation
- cell cycle arrest